NXGL vs. MBOT, SSKN, PETV, GCTK, BTCY, TTOO, PSTV, NURO, MHUA, and OSA
Should you be buying NEXGEL stock or one of its competitors? The main competitors of NEXGEL include Microbot Medical (MBOT), STRATA Skin Sciences (SSKN), PetVivo (PETV), GlucoTrack (GCTK), Biotricity (BTCY), T2 Biosystems (TTOO), Plus Therapeutics (PSTV), NeuroMetrix (NURO), Meihua International Medical Technologies (MHUA), and ProSomnus (OSA). These companies are all part of the "surgical & medical instruments" industry.
NEXGEL (NASDAQ:NXGL) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.
NEXGEL has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
2.2% of NEXGEL shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 27.2% of NEXGEL shares are owned by insiders. Comparatively, 10.6% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, NEXGEL had 6 more articles in the media than Microbot Medical. MarketBeat recorded 9 mentions for NEXGEL and 3 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.64 beat NEXGEL's score of 0.42 indicating that Microbot Medical is being referred to more favorably in the news media.
Microbot Medical has a consensus price target of $7.00, indicating a potential upside of 644.60%. Given Microbot Medical's higher probable upside, analysts clearly believe Microbot Medical is more favorable than NEXGEL.
Microbot Medical has a net margin of 0.00% compared to NEXGEL's net margin of -67.48%. NEXGEL's return on equity of -54.71% beat Microbot Medical's return on equity.
NEXGEL has higher revenue and earnings than Microbot Medical. NEXGEL is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Microbot Medical received 345 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Summary
Microbot Medical beats NEXGEL on 9 of the 16 factors compared between the two stocks.
Get NEXGEL News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
